Results of Buparlisib Plus Fulvestrant in HR+/HER2- Breast Cancer

Video

Ruth O’Regan, MD, discusses results of BELLE-3, a phase III study of buparlisib (BKM120) plus fulvestrant (Faslodex) in postmenopausal women with hormone receptor (HR)-positive, HER2-negative breast cancer.

Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
Related Content